Docoh
Loading...

GSTC GlobeStar Therapeutics

Filed: 20 Sep 21, 8:16am


 


UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549


FORM 8-K


CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934


Date of Report (Date of earliest event reported) September 20, 2021



GlobeStar Therapeutics Corporation

(Exact name of registrant as specified in its charter)

 

Wyoming

333-170315

27-3480481

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)


719 Jadwin Avenue

Richland, WA 99352

(Address of principal executive offices)(Zip Code)


206-451-1970

(Registrant’s telephone number, including area code)

www.globestarthera.com


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common

GSTC

N/A


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company              


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.


 



Item 8.01 Other Events.


The Company is devoting all its available resources for FDA approval to enable marketing the patented treatment for Multiple Sclerosis. Attached is Multiple Sclerosis drug development information and our mission – our technology.


Item 9.01 Financial Statements and Exhibits.


(d) Exhibits.


99.1Multiple Sclerosis Drug Development Information September 2021
  
104Cover Page Interactive Data File (embedded within the Inline XBRL document)



SIGNATURE


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


 

GlobeStar Therapeutics Corporation

 

 

Date: September 20, 2021

By:  /s/ David Croom

 

Name:  David Croom

Title:  Executive Vice President


- 2 -